JQ1 treatment combined with the inhibition of the WNT/β-catenin/TCF signaling pathway by β-catenin siRNAs or with the inhibition of the MEK/ERK pathway by the MEK inhibitor trametinib more significantly downregulated the expression of c-MYC and induced a more potent antiproliferative effect than single treatment in CRC cells [98]. Here, MAP2K7 is linked to colorectal carcinoma.